KRTL Holding Group Advances RAYEL Into Next Phase with Definitive CIQ Agreement
https://www.globenewswire.com/news-release/20...ement.html
Lakewood, CO, Oct. 05, 2026 (GLOBE NEWSWIRE) -- KRTL Holding Group Inc. (OTC: KRTL) ("KRTL" or the "Company"
today announced that its wholly owned subsidiaries, KRTL International Corp. and KRTL Biotech Inc., have executed a definitive strategic partnership agreement with CENTRO DE INVESTIGACIONES QUIMICAS, S.R.L. ("CIQ" for the continued development and commercialization of the RAYEL platform.
The agreement marks an important transition for RAYEL. What began under a Memorandum of Understanding now moves into a binding framework designed to support U.S. commercialization, manufacturing evaluation, strategic partnerships, regulatory coordination, capital development and additional potential applications for the platform.
For KRTL, the timing is significant. The Company has been building the pieces around RAYEL - strengthening its U.S. regulatory and pharmaceutical/API capabilities, organizing the platform’s technical and commercial record, developing potential partner pathways and opening discussions with universities regarding potential research collaboration.
KRTL Holding Group management stated: “This agreement brings together work that has been developing on several fronts. We have CIQ’s scientific and technical foundation, a defined U.S. commercialization strategy, growing regulatory and API expertise through KRTL Biotech, and active discussions with universities. We can now begin bringing those pieces together around RAYEL and evaluating where the platform has the strongest opportunity to advance.”
The Platform and the Path
Under the agreement, KRTL will lead the U.S. commercialization pathway for RAYEL, while CIQ continues its scientific and technical role. The parties will coordinate strategy and make material project decisions together.
KRTL and CIQ are evaluating multiple potential uses and commercial pathways for RAYEL.
The platform has a documented beverage-facing TTB pathway for its documented product scope, while the parties are also evaluating how RAYEL could be developed across additional pharmaceutical/API-oriented and other potential applications.
Rather than building RAYEL around a single prospective market, KRTL intends to evaluate where the platform, its scientific record and future research may have the strongest commercial fit.
The Opportunity Around RAYEL
That strategy is taking shape against a growing global market for plant-derived extracts.
MarketsandMarkets estimates the global plant extracts market at approximately $47.54 billion in 2025 and projects it to reach $85.28 billion by 2030, representing a 12.4% compound annual growth rate. The market spans applications including food and beverages, pharmaceuticals, dietary supplements and cosmetics. Source: MarketsandMarkets
KRTL has been working to build the capabilities needed to evaluate RAYEL within that broader environment.
Through KRTL Biotech, the Company engaged Justin Abril as President-Designate and Strategic Regulatory & API Consultant, adding experience in regulatory strategy, pharmaceutical/API development planning, API/CMC documentation, controlled-substance compliance planning, import/export pathway review and partner diligence.
KRTL is also in active discussions with universities regarding potential research collaboration related to RAYEL, creating another potential avenue for scientific and technical development around the platform.
Put together, the strategy is becoming clearer: CIQ provides the scientific and technical foundation; KRTL is building the commercial, regulatory, research and partner-development infrastructure around it; and the definitive agreement provides the framework for those efforts to move forward together.
What Comes Next
The focus now turns to translating that framework into qualified opportunities.
KRTL and CIQ will continue developing the RAYEL technical and commercial record while evaluating research, manufacturing, strategic and commercial relationships in the United States. As individual opportunities mature, they can move into project-specific agreements appropriate to the particular pathway.
KRTL management added: “Signing the agreement is a milestone, but what matters now is what we build from it. Our focus is getting RAYEL in front of the right researchers, technical groups, manufacturers and commercial partners and allowing the science, the documentation and the market opportunity to guide where we go next.”
Any regulated manufacturing, controlled-substance handling, testing, importation, formulation, pharmaceutical/API development or distribution would be performed through appropriately qualified and authorized external parties.
https://www.globenewswire.com/news-release/20...ement.html
Lakewood, CO, Oct. 05, 2026 (GLOBE NEWSWIRE) -- KRTL Holding Group Inc. (OTC: KRTL) ("KRTL" or the "Company"
today announced that its wholly owned subsidiaries, KRTL International Corp. and KRTL Biotech Inc., have executed a definitive strategic partnership agreement with CENTRO DE INVESTIGACIONES QUIMICAS, S.R.L. ("CIQ" for the continued development and commercialization of the RAYEL platform. The agreement marks an important transition for RAYEL. What began under a Memorandum of Understanding now moves into a binding framework designed to support U.S. commercialization, manufacturing evaluation, strategic partnerships, regulatory coordination, capital development and additional potential applications for the platform.
For KRTL, the timing is significant. The Company has been building the pieces around RAYEL - strengthening its U.S. regulatory and pharmaceutical/API capabilities, organizing the platform’s technical and commercial record, developing potential partner pathways and opening discussions with universities regarding potential research collaboration.
KRTL Holding Group management stated: “This agreement brings together work that has been developing on several fronts. We have CIQ’s scientific and technical foundation, a defined U.S. commercialization strategy, growing regulatory and API expertise through KRTL Biotech, and active discussions with universities. We can now begin bringing those pieces together around RAYEL and evaluating where the platform has the strongest opportunity to advance.”
The Platform and the Path
Under the agreement, KRTL will lead the U.S. commercialization pathway for RAYEL, while CIQ continues its scientific and technical role. The parties will coordinate strategy and make material project decisions together.
KRTL and CIQ are evaluating multiple potential uses and commercial pathways for RAYEL.
The platform has a documented beverage-facing TTB pathway for its documented product scope, while the parties are also evaluating how RAYEL could be developed across additional pharmaceutical/API-oriented and other potential applications.
Rather than building RAYEL around a single prospective market, KRTL intends to evaluate where the platform, its scientific record and future research may have the strongest commercial fit.
The Opportunity Around RAYEL
That strategy is taking shape against a growing global market for plant-derived extracts.
MarketsandMarkets estimates the global plant extracts market at approximately $47.54 billion in 2025 and projects it to reach $85.28 billion by 2030, representing a 12.4% compound annual growth rate. The market spans applications including food and beverages, pharmaceuticals, dietary supplements and cosmetics. Source: MarketsandMarkets
KRTL has been working to build the capabilities needed to evaluate RAYEL within that broader environment.
Through KRTL Biotech, the Company engaged Justin Abril as President-Designate and Strategic Regulatory & API Consultant, adding experience in regulatory strategy, pharmaceutical/API development planning, API/CMC documentation, controlled-substance compliance planning, import/export pathway review and partner diligence.
KRTL is also in active discussions with universities regarding potential research collaboration related to RAYEL, creating another potential avenue for scientific and technical development around the platform.
Put together, the strategy is becoming clearer: CIQ provides the scientific and technical foundation; KRTL is building the commercial, regulatory, research and partner-development infrastructure around it; and the definitive agreement provides the framework for those efforts to move forward together.
What Comes Next
The focus now turns to translating that framework into qualified opportunities.
KRTL and CIQ will continue developing the RAYEL technical and commercial record while evaluating research, manufacturing, strategic and commercial relationships in the United States. As individual opportunities mature, they can move into project-specific agreements appropriate to the particular pathway.
KRTL management added: “Signing the agreement is a milestone, but what matters now is what we build from it. Our focus is getting RAYEL in front of the right researchers, technical groups, manufacturers and commercial partners and allowing the science, the documentation and the market opportunity to guide where we go next.”
Any regulated manufacturing, controlled-substance handling, testing, importation, formulation, pharmaceutical/API development or distribution would be performed through appropriately qualified and authorized external parties.
